Long term safety of romiplostim in patients with immune thrombocytopenia in Nordic countries: Nordic Country Patient Registry for Immune Thrombocytopenia (NCPRITP)
Latest Information Update: 21 Sep 2017
At a glance
- Drugs Romiplostim (Primary)
- Indications Idiopathic thrombocytopenic purpura
- Focus Adverse reactions
- 21 Sep 2017 New trial record
- 30 Aug 2017 According to trial design presented at the 33rd International Conference on Pharmacoepidemiology and Therapeutic Risk Management, 3749 patients have been enrolled.
- 30 Aug 2017 Trial design presented at the 33rd International Conference on Pharmacoepidemiology and Therapeutic Risk Management.